Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.
Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
Type:
Grant
Filed:
May 25, 2012
Date of Patent:
September 6, 2022
Assignee:
CAMURUS AB
Inventors:
Fredrik Tiberg, Catalin Nistor, Markus Johnsson
Abstract: Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis.
Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
Type:
Grant
Filed:
April 29, 2019
Date of Patent:
July 5, 2022
Assignee:
Cerenis Therapeutics Holding S.A.
Inventors:
Jean-Louis Dasseux, Rose Ackermann, Daniela Carmen Oniciu
Abstract: The present invention relates to compositions and methods for treating autoimmune, microbial, metabolic, neoplastic, and posttraumatic diseases mediated by inflammation in a subject. Compositions and methods including at least one importin beta-selective nuclear transport modifier (NTM) and/or at least one importin alpha-selective NTM, and/or at least one importin alpha-specific NTM, and/or at least one inhibitor of importin alpha and importin beta complex formation may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease or abrogation of inflammation.
Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
Type:
Grant
Filed:
May 9, 2017
Date of Patent:
June 7, 2022
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
Abstract: The present invention relates to novel short chain peptides of formula (I) which can be useful as a vaccine when in conjugation with suitable immunogenic carrier and suitable adjuvant. These are useful for the treatment for the PCSK9 mediated diseases.
Abstract: Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for, the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
Type:
Grant
Filed:
November 15, 2019
Date of Patent:
May 3, 2022
Assignee:
INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
David Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
Abstract: Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided.
Abstract: The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISF” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present.
Abstract: The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.
Abstract: Provided is a technique for highly expressing a target protein in a plant cell by using a glycosylation domain, a recombinant vector comprising a gene encoding a fusion protein of a glycosylation domain and a target protein, a recombinant cell, a transformed plant, and a method of producing a target protein using these.
Abstract: The present invention pertains to inter alia therapeutic delivery vesicles, for instance exosomes or microvesicles, comprising polypeptide constructs, methods for producing said therapeutic delivery vesicles, pharmaceutical compositions and medical uses thereof. The therapeutic polypeptide constructs comprised in the extracellular delivery vesicles enable sequestering target molecules of interest, to treat e.g. neuro-inflammatory diseases and cancer.
Type:
Grant
Filed:
April 10, 2014
Date of Patent:
March 15, 2022
Assignee:
Evox Therapeutics Ltd
Inventors:
Samir El Andaloussi, Oscar Wiklander, Joel Nordin, Edvard Smith, Karl-Henrik Grinnemo, Oscar Simonson
Abstract: The present invention relates to use of a human C3a receptor agonist in the manufacture of a medicament for the treatment or prevention of an ischemic brain injury, wherein the medicament is formulated for intranasal delivery, human C3a receptor agonist for such use, as well as devices for intranasal administration comprising a human C3a receptor agonist and kits comprising such devices.
Type:
Grant
Filed:
November 20, 2017
Date of Patent:
March 8, 2022
Inventors:
Marcela Pekna, Milos Pekny, Anna Stokowska
Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.
Type:
Grant
Filed:
May 7, 2020
Date of Patent:
February 22, 2022
Assignee:
Laboratoire Francais du Fractionnement et des Biotechnologies
Abstract: The present invention relates to a protein derived from lactic acid bacteria and a method for producing the same. The lactic acid bacteria-derived protein of the present invention is a purified protein isolated from lactic acid bacteria (Lactobacillus rhamnosus) having an excellent therapeutic effect against colorectal cancer. It has been demonstrated to have a remarkable effect against colorectal diseases, and thus is expected to be widely used as a natural protein therapeutic agent against colorectal diseases in the medical field.
Abstract: Field of application: The invention relates to medicine and pharmacy and allows to obtain new pharmaceutical compositions based on polymyxin for the treatment of severe infectious diseases, but not possessing nephrotoxic properties in therapeutic doses. Technical result: New combined dosage forms based on the antibiotic polymyxin with low nephrotoxicity and high activity.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
December 7, 2021
Inventors:
Boris Farber, Ilya Ruvimovich Kleyn, Artur Viktorovich Martynov
Abstract: The present invention provides peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates comprise a moiety such as a PEG moiety, an imaging agent, or a therapeutic agent. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue. Compositions and kits containing the peptide conjugates of the present invention are also provided herein.
Type:
Grant
Filed:
December 12, 2018
Date of Patent:
November 30, 2021
Assignee:
The Regents of the University of California
Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
November 23, 2021
Assignee:
Arrowhead Pharmaceuticals, Inc.
Inventors:
Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
Abstract: The present application belongs to the field of medicine. The present application relates to a GLP-1 polypeptide having GLP-1 receptor agonist activity and the use thereof. The present application further relates to a pharmaceutical composition comprising the GLP-1 polypeptide. In particular, the present application relates to a GLP-1 polypeptide having GLP-1 receptor agonist activity, or a pharmaceutically acceptable salt thereof, characterized in that the GLP-1 polypeptide has a mutation from threonine to proline at the position corresponding to the 13th position of the amino acid sequence of GLP-1.